{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:46:49Z","timestamp":1779896809920,"version":"3.53.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,22]]},"DOI":"10.7759\/cureus.60861","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:22:35Z","timestamp":1716394955000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Sofosbuvir and Velpatasvir Combination in the Treatment of Hepatitis C Virus (HCV) in Chronic Kidney Disease (CKD) Patients"],"prefix":"10.7759","author":[{"given":"Noor","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilaram","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift AP","year":"2017","unstructured":"Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017, 14:122-32. 10.1038\/nrgastro.2016.176","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.180257","article-title":"The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses","volume":"5","author":"Al Kanaani Z","year":"2018","unstructured":"Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. R Soc Open Sci. 2018, 5:10.1098\/rsos.180257","journal-title":"R Soc Open Sci"},{"key":"ref3","unstructured":"Regional action plan for the implementation of the global health sector strategy on viral hepatitis 2017-2021. (2017). Accessed. May 20, 2024: https:\/\/iris.who.int\/handle\/10665\/258729."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-3918-z","article-title":"Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES","volume":"61","author":"Rogal SS","year":"2016","unstructured":"Rogal SS, Yan P, Rimland D, Lo Re V 3rd, Al-Rowais H, Fried L, Butt AA. Incidence and progression of chronic kidney disease after hepatitis C seroconversion: results from ERCHIVES. Dig Dis Sci. 2016, 61:930-6. 10.1007\/s10620-015-3918-z","journal-title":"Dig Dis Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100790","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee JJ","year":"2014","unstructured":"Lee JJ, Lin MY, Chang JS, et al.. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014, 9:10.1371\/journal.pone.0100790","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz E","year":"2020","unstructured":"Lawitz E, Flisiak R, Abunimeh M, et al.. Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020, 40:1032-41. 10.1111\/liv.14320","journal-title":"Liver Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.86428","article-title":"Molecular epidemiology of hepatitis C virus genotypes among chronically infected patients in Pakistan","volume":"12","author":"Khan S","year":"2019","unstructured":"Khan S, Ali I, Badshah M, et al.. Molecular epidemiology of hepatitis C virus genotypes among chronically infected patients in Pakistan. Jundishapur J Microbiol. 2019, 12:1-7. 10.5812\/jjm.86428","journal-title":"Jundishapur J Microbiol"},{"key":"ref8","unstructured":"EPCLUSA (sofosbuvir and velpatasvir) tablets, for oral use. (2017). Accessed. May 20, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208341s007lbl.pdf."},{"key":"ref9","unstructured":"World Health Organization. Progress report on access to hepatitis C treatment. focus on overcoming barriers in low- and middle-income countries. (2018). Accessed: May 20, 2024: https:\/\/iris.who.int\/handle\/10665\/260445."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld JJ","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, et al.. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015, 373:2599-607. 10.1056\/NEJMoa1512610","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs) - a new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler U","year":"2018","unstructured":"Spengler U. Direct antiviral agents (DAAs) - a new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018, 183:118-26. 10.1016\/j.pharmthera.2017.10.009","journal-title":"Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61113-1","article-title":"The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics","volume":"56","author":"MT Cornpropost","year":"2012","unstructured":"MT Cornpropost, Jill Denning, D Clemons, et al.. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics. J Hepatol. 2012, 56:433. 10.1016\/S0168-8278(12)61113-1","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13968","article-title":"Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: a systematic review and meta-analysis","volume":"27","author":"De A","year":"2022","unstructured":"De A, Roy A, Verma N, et al.. Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: a systematic review and meta-analysis. Nephrology (Carlton). 2022, 27:82-9. 10.1111\/nep.13968","journal-title":"Nephrology (Carlton)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Aude Desnoyer","year":"2016","unstructured":"Aude Desnoyer, Dan Pospai, Minh Patrick L\u00ea, et al.. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016, 65:40-7. 10.1016\/j.jhep.2016.02.044","journal-title":"J Hepatol"},{"key":"ref15","article-title":"Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan","volume":"13","author":"Mandhwani R","year":"2020","unstructured":"Mandhwani R, Hanif FM, Lail G, et al.. Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. Gastroenterol Hepatol Bed Bench. 2020, 13:141-6.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2019.10.004","article-title":"Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney tran","volume":"10","author":"Gaur N","year":"2020","unstructured":"Gaur N, Malhotra V, Agrawal D, et al.. Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney tran. J Clin Exp Hepatol. 2020, 10:189-93. 10.1016\/j.jceh.2019.10.004","journal-title":"J Clin Exp Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45680","article-title":"Sofosbuvir and velpatasvir regimen outcome for chronic hepatitis C patients with end-stage renal disease undergoing hemodialysis","volume":"15","author":"Shahid S","year":"2023","unstructured":"Shahid S, Asghar S, Mahmood T, Fatima M, Rasheed A, Asghar S. Sofosbuvir and velpatasvir regimen outcome for chronic hepatitis C patients with end-stage renal disease undergoing hemodialysis. Cureus. 2023, 15:10.7759\/cureus.45680","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia SM","year":"2019","unstructured":"Borgia SM, Dearden J, Yoshida EM, et al.. Sofosbuvir\/velpatasvir for 12\u202fweeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019, 71:660-5. 10.1016\/j.jhep.2019.05.028","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10111381","article-title":"An updated view on the antiviral therapy of hepatitis C in chronic kidney disease","volume":"10","author":"Fabrizi F","year":"2021","unstructured":"Fabrizi F, Cerutti R, Messa P. An updated view on the antiviral therapy of hepatitis C in chronic kidney disease. Pathogens. 2021, 10:10.3390\/pathogens10111381","journal-title":"Pathogens"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253314-efficacy-of-sofosbuvir-and-velpatasvir-combination-in-the-treatment-of-hepatitis-c-virus-hcv-in-chronic-kidney-disease-ckd-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:22:40Z","timestamp":1716394960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253314-efficacy-of-sofosbuvir-and-velpatasvir-combination-in-the-treatment-of-hepatitis-c-virus-hcv-in-chronic-kidney-disease-ckd-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.60861","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}